Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

12.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

2.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.0K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.4K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.4K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

438
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
438
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

68
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
68
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CVAE-guided triage and modular classifiers for multimodal ASD detection.

Computers in biology and medicine·2026
Same author

An ABCB11 variant registry and novel knockin mouse model of PFIC2 based on the clinically relevant ABCB11 E297G variant.

Journal of lipid research·2025
Same author

How does machine learning augment alchemical binding free energy calculations?

Future medicinal chemistry·2025
Same author

Perspectives on current approaches to virtual screening in drug discovery.

Expert opinion on drug discovery·2024
Same author

Stimulated Full-Thickness Cutaneous Wound Healing with Bioactive Dressings of Zinc and Cobalt Ion-Doped Bioactive Glass-Coated Eggshell Membranes in a Diabetic Rabbit Model.

ACS biomaterials science & engineering·2024
Same author

Recent trends of stem cell therapies in the management of orthopedic surgical challenges.

International journal of surgery (London, England)·2024

Related Experiment Video

Updated: Mar 15, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

Automatically updating predictive modeling workflows support decision-making in drug design.

Ingo Muegge1, Jörg Bentzien1, Prasenjit Mukherjee1

  • 1Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, CT 06877-0368, USA.

Future Medicinal Chemistry
|September 2, 2016
PubMed
Summary

Automated predictive models enhance drug discovery decisions by requiring minimal input and maintenance. Tailored models, frequent updates, and consensus approaches ensure reliable predictions for compound optimization.

Keywords:
QSAR modelcomputational chemistrydrug designhuman dose predictionmolecular dockingqualified data

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.5K

Related Experiment Videos

Last Updated: Mar 15, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.5K

Area of Science:

  • Computational chemistry
  • cheminformatics
  • Drug discovery

Background:

  • Predictive models are crucial for early decision-making in drug discovery.
  • Current model building often requires significant input and technical maintenance.
  • In silico models supporting rapid structure-activity relationship (SAR) cycles degrade quickly.

Purpose of the Study:

  • To propose automated model building with minimal input and low maintenance.
  • To optimize predictive models for specific compound optimization questions.
  • To enhance decision-making by integrating predictive modeling with structural information.

Main Methods:

  • Development of automated model building pipelines.
  • Tailoring models for specific compound optimization tasks.
  • Utilizing 2-bin classification for qualitative predictions.
  • Integrating predictive modeling outputs with structural data.
  • Implementing frequent automated model updates.
  • Employing consensus modeling approaches.
  • Combining qualified and nonqualified data.

Main Results:

  • Automated models reduce technical maintenance and input requirements.
  • Tailored models and 2-bin classification improve prediction relevance.
  • Integration with structural information enhances decision-making.
  • Frequent updates and consensus methods maintain and increase prediction confidence.
  • Combined data usage optimizes information utilization.
  • Dose predictions offer a holistic decision-making alternative.

Conclusions:

  • Automated, tailored predictive models are essential for efficient drug discovery.
  • Frequent updates and consensus strategies are key to sustained model performance.
  • Integrating diverse data types and structural information improves predictive accuracy and decision quality.